Using lower cost statins improves outcomes for normal cholesterol non-diabetic patients.

Published in: Expert review of pharmacoeconomics & outcomes research (2017)

Under budget constraints, using Simvastatin instead of branded Rosuvastatin resulted in a 47 fold increase of prevention of MACE for the entire IUP. These results should be considered while initiating statin therapy in this target population.

Keyphrases

cardiovascular disease
low density lipoprotein
coronary artery disease
type diabetes
metabolic syndrome
adipose tissue
cell therapy
insulin resistance
weight loss